Atom Bio­science rais­es $83M in Se­ries D for URAT1 in­hibitor in chron­ic gout treat­ment

Atom Bio­science has pulled in $83 mil­lion in Se­ries D fi­nanc­ing for its URAT1 in­hibitor for chron­ic gout, the com­pa­ny an­nounced Mon­day, with the mon­ey go­ing to­ward fin­ish­ing its piv­otal tri­als for the drug.

The Chi­nese com­pa­ny has raised $165 mil­lion to­tal over its fi­nanc­ing rounds, thanks to in­vestors like Kaitai Cap­i­tal, For­tune Cap­i­tal, Hua­jin In­vest­ment, Uni­for­tune and NNFE In­vest­ment.

Atom tout­ed ABP-671’s abil­i­ty to re­duce serum uric acid lev­els in urine by in­hibit­ing URAT1, the pri­ma­ry end­point in tri­als. Chron­ic gout is caused by el­e­vat­ed lev­els of the acid, al­so known as hy­pe­r­uricemia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER